Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.

It works as a selective microsomal triglyceride transfer protein inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.

It is supplied as an oral solution. It is not intended for use in humans or cats.

On January 5 2007, the FDA approved Slentrol, the first time the FDA has approved a drug for obese dogs.